{"id":1410,"date":"2025-12-05T18:45:04","date_gmt":"2025-12-05T18:45:04","guid":{"rendered":"https:\/\/admit-therapeutics.com\/?p=1410"},"modified":"2025-12-05T18:48:25","modified_gmt":"2025-12-05T18:48:25","slug":"admit-therapeutics-obtains-clia-certification-opening-doors-to-the-u-s-healthcare-market","status":"publish","type":"post","link":"https:\/\/admit-therapeutics.com\/en\/admit-therapeutics-obtains-clia-certification-opening-doors-to-the-u-s-healthcare-market\/","title":{"rendered":"ADmit Therapeutics Obtains CLIA Certification, Opening Doors to the U.S. Healthcare Market"},"content":{"rendered":"\n<p>Barcelona (Spain), December\u00a04, 2025. ADmit Therapeutics today announced that it has obtained the\u00a0<strong>CLIA (Clinical Laboratory Improvement Amendments) Certificate<\/strong>. This accreditation, granted by the US Centers for Medicare &amp; Medicaid Services (CMS), confirms compliance with the most\u00a0<strong>stringent standards for analytical quality and reliability<\/strong>.<\/p>\n\n\n\n<p>Obtaining CLIA certification is a crucial milestone that transforms ADmit Therapeutics into a provider with&nbsp;<strong>full regulatory validity<\/strong>&nbsp;for the US market.<\/p>\n\n\n\n<p>&#8220;This certification is not just a seal of quality; it is an&nbsp;<strong>essential commercial passport<\/strong>&nbsp;that guarantees the analytical excellence of our processes and allows us to offer our advanced technology, the MAP-AD<sup>\u00ae<\/sup>&nbsp;Test, to patients and healthcare providers in the United States,&#8221; stated Marta Barrachina, CEO of the company.<\/p>\n\n\n\n<p>The CLIA certificate ensures that all analyses and validation of results performed by ADmit Therapeutics on samples from&nbsp;<strong>US patients<\/strong>&nbsp;comply with U.S. federal requirements regarding accuracy, reliability, and timeliness.<\/p>\n\n\n\n<p>This accreditation underscores ADmit Therapeutics\u2019 commitment to the highest international quality standards and its position as a strategic global partner in diagnostics and research.<\/p>\n\n\n\n<p>The CLIA certification adds to the CAP accreditation clearance in 2024 and strengthens the laboratory&#8217;s capacity to offer services of the MAP-AD<sup>\u00ae<\/sup> Test&nbsp;in the US market.<\/p>\n\n\n\n<p><strong>What is CLIA?<\/strong><\/p>\n\n\n\n<p>The Clinical Laboratory Improvement Amendments of 1988 (CLIA) and its implementing regulations at 42 CFR Part 493 are federal laws and regulations that apply to all U.S. and CLIA-certified international laboratories or sites that test specimens from humans (e.g., blood, tissue, and body fluid) to assess health or to diagnose, prevent, or treat disease. The Centers for Medicare &amp; Medicaid Services (CMS), in collaboration with the Centers for Disease Control (CDC) and the Food &amp; Drug Administration (FDA), support the CLIA program to ensure quality laboratory testing.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Barcelona (Spain), December\u00a04, 2025. ADmit Therapeutics today announced that it has obtained the\u00a0CLIA (Clinical Laboratory Improvement Amendments) Certificate. This accreditation, granted by the US Centers for Medicare &amp; Medicaid Services (CMS), confirms compliance with the most\u00a0stringent standards for analytical quality and reliability. Obtaining CLIA certification is a crucial milestone that transforms ADmit Therapeutics into a [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1410","post","type-post","status-publish","format-standard","hentry","category-sin-categorizar"],"acf":[],"_links":{"self":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/posts\/1410","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/comments?post=1410"}],"version-history":[{"count":3,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/posts\/1410\/revisions"}],"predecessor-version":[{"id":1413,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/posts\/1410\/revisions\/1413"}],"wp:attachment":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/media?parent=1410"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/categories?post=1410"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/tags?post=1410"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}